These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

96 related items for PubMed ID: 1661346

  • 1. [Bi-specific F(ab')2 enhances cytolytic activities of LAK cells against human small cell lung cancer (SCLC)].
    Azuma A, Niitani H.
    Nihon Kyobu Shikkan Gakkai Zasshi; 1991 Sep; 29(9):1132-7. PubMed ID: 1661346
    [Abstract] [Full Text] [Related]

  • 2. [The enhancement of cytolytic activity in lymphokine activated killer cells using bispecific F(ab')2].
    Azuma A.
    Nihon Ika Daigaku Zasshi; 1991 Dec; 58(6):663-72. PubMed ID: 1663120
    [Abstract] [Full Text] [Related]

  • 3. Induction of intercellular adhesion molecule 1 on small cell lung carcinoma cell lines by gamma-interferon enhances spontaneous and bispecific anti-CD3 x antitumor antibody-directed lymphokine activated killer cell cytotoxicity.
    Azuma A, Yagita H, Matsuda H, Okumura K, Niitani H.
    Cancer Res; 1992 Sep 15; 52(18):4890-4. PubMed ID: 1381273
    [Abstract] [Full Text] [Related]

  • 4. Potentiation of long-term-cultured lymphokine-activated killer cell cytotoxicity against small-cell lung carcinoma by anti-CD3 x anti-(tumor-associated antigen) bispecific antibody.
    Azuma A, Yagita H, Okumura K, Kudoh S, Niitani H.
    Cancer Immunol Immunother; 1994 May 15; 38(5):294-8. PubMed ID: 7909278
    [Abstract] [Full Text] [Related]

  • 5. Bispecific F (ab')2 monomer prepared with anti-CD3 and anti-tumor monoclonal antibodies is most potent in induction of cytolysis of human T cells.
    Nitta T, Yagita H, Azuma T, Sato K, Okumura K.
    Eur J Immunol; 1989 Aug 15; 19(8):1437-41. PubMed ID: 2528460
    [Abstract] [Full Text] [Related]

  • 6. [Induction of cytotoxicity from human lymphocytes coated with bispecific antibody against human glioma cells].
    Nitta T, Ishizawa A, Ito M, Sato K, Yagita H, Kumura K.
    No Shinkei Geka; 1990 Nov 15; 18(11):1001-6. PubMed ID: 2247192
    [Abstract] [Full Text] [Related]

  • 7. Augmentation of lymphokine-activated killer cell cytotoxicity by monoclonal antibodies against human small cell lung carcinoma.
    Tong AW, Lee JC, Wang RM, Ordonez G, Stone MJ.
    Cancer Res; 1989 Aug 01; 49(15):4103-8. PubMed ID: 2545333
    [Abstract] [Full Text] [Related]

  • 8. Trispecific F(ab')3 derivatives that use cooperative signaling via the TCR/CD3 complex and CD2 to activate and redirect resting cytotoxic T cells.
    Tutt A, Stevenson GT, Glennie MJ.
    J Immunol; 1991 Jul 01; 147(1):60-9. PubMed ID: 1675655
    [Abstract] [Full Text] [Related]

  • 9. CD3 directed bispecific antibodies induce increased lymphocyte-endothelial cell interactions in vitro.
    Molema G, Tervaert JW, Kroesen BJ, Helfrich W, Meijer DK, de Leij LF.
    Br J Cancer; 2000 Jan 01; 82(2):472-9. PubMed ID: 10646907
    [Abstract] [Full Text] [Related]

  • 10. Triggering of the cytotoxic activity of murine natural killer and lymphokine-activated killer cells through the NK2.1 antigen.
    Morelli L, Lemieux S.
    J Immunol; 1993 Dec 15; 151(12):6783-93. PubMed ID: 8258690
    [Abstract] [Full Text] [Related]

  • 11. Effective adoptive immunotherapy by T-LAK cells retargeted with bacterial superantigen-conjugated antibody to MUC1 in xenografted severe combined immunodeficient mice.
    Shinoda M, Kudo T, Suzuki M, Katayose Y, Sakurai N, Saeki H, Kodama H, Fukuhara K, Imai K, Hinoda Y, Matsuno S.
    Cancer Res; 1998 Jul 01; 58(13):2838-43. PubMed ID: 9661899
    [Abstract] [Full Text] [Related]

  • 12. Human T-lymphocytes targeted against an established human ovarian carcinoma with a bispecific F(ab')2 antibody prolong host survival in a murine xenograft model.
    Mezzanzanica D, Garrido MA, Neblock DS, Daddona PE, Andrew SM, Zurawski VR, Segal DM, Wunderlich JR.
    Cancer Res; 1991 Oct 15; 51(20):5716-21. PubMed ID: 1833054
    [Abstract] [Full Text] [Related]

  • 13. Visualization of effective tumor targeting by CD8+ natural killer T cells redirected with bispecific antibody F(ab')(2)HER2xCD3.
    Scheffold C, Kornacker M, Scheffold YC, Contag CH, Negrin RS.
    Cancer Res; 2002 Oct 15; 62(20):5785-91. PubMed ID: 12384539
    [Abstract] [Full Text] [Related]

  • 14. Targeting gastrin-releasing peptide receptors on small cell lung cancer cells with a bispecific molecule that activates polyclonal T lymphocytes.
    Zhou J, Chen J, Zhong R, Mokotoff M, Shultz LD, Ball ED.
    Clin Cancer Res; 2006 Apr 01; 12(7 Pt 1):2224-31. PubMed ID: 16609038
    [Abstract] [Full Text] [Related]

  • 15. Anti-CD3 x anti-tumor F(ab')2 bifunctional antibody activates and retargets tumor-infiltrating lymphocytes.
    Chapoval AI, Nelson H, Thibault C.
    J Immunol; 1995 Aug 01; 155(3):1296-303. PubMed ID: 7636196
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Increased lysis of melanoma by in vivo-elicited human lymphokine-activated killer cells after addition of antiganglioside antibodies in vitro.
    Harel W, Shau H, Hadley CG, Morgan AC, Reisfeld RA, Cheresh DA, Mitchell MS.
    Cancer Res; 1990 Oct 01; 50(19):6311-5. PubMed ID: 2400994
    [Abstract] [Full Text] [Related]

  • 19. Two distinct porcine natural killer lytic trigger molecules as PNK-E/G7 molecular complex.
    Wierda WG, Johnson BD, Dato ME, Kim YB.
    Cell Immunol; 1993 Feb 01; 146(2):270-83. PubMed ID: 8174170
    [Abstract] [Full Text] [Related]

  • 20. Lymphokine-activated killer activity in long-term cultures with anti-CD3 plus interleukin 2: identification and isolation of effector subsets.
    Ochoa AC, Hasz DE, Rezonzew R, Anderson PM, Bach FH.
    Cancer Res; 1989 Feb 15; 49(4):963-8. PubMed ID: 2521457
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.